$5.660
-0.294 (-5.19%)收盤時
SRTA 資訊
SRTA 事件
Strata Adjusts FY26 EBITDA Guidance to $29M-$33M
Backs FY26 adjusted EBITDA view $29M-$33M. "The underlying strength of our transformed economic model is finally shining through as we began generating operating cash flow this quarter. Our quality of earnings and cash conversion will only improve in the coming quarters as we clear the last remaining Passenger divestiture transaction-related outflows," said Will Heyburn, Co-CEO and CFO. "Our Clinical division showed especially strong sequential growth, with Gross Profit up nearly 30% versus Q4 2025, driven by a combination of new customer wins, a rebound in overall industry organ donors and continued industry mix shift towards third-party surgical recovery and NRP, where Strata is a market leader."
Company Reports Q1 Revenue of $67.38M, Exceeding Expectations
Reports Q1 revenue $67.38M, consensus $63.67M. "We are pleased to report Q1 results that came in ahead of our expectations, reflecting both strong execution on our growth plan and improving industry dynamics," said Melissa Tomkiel, Co-CEO and General Counsel. "Operationally, we're making great progress optimizing how we deliver our end-to-end transplant service offering."
Raises EBITDA Outlook to $29M-$33M
Raises adjusted EBITDA view $29M-$33M from $28M-$32M; Sees free cash flow, before aircraft and engine acquisitions of $15M-22M.
Will Heyburn: Company Aims for 30% Annual EBITDA Growth
"We continue to demonstrate our ability to achieve and exceed the ambitious goals we set for ourselves, both for organic growth, which at 35.3% this quarter was significantly ahead of our targets, as well as for our M&A platform," said Will Heyburn, Co-CEO and CFO. "We're seeing smaller competitors proactively reach out, hoping to join forces which serves to enhance our already strong acquisition pipeline. At the same time, we are working diligently towards closing multiple opportunities currently under exclusivity that are operating directly in our core competency areas and are actionable at mid-single digit multiples of Adjusted EBITDA. We expect that our successful continued execution on these acquisition opportunities will significantly accelerate our growth trajectory, enabling us to maintain an average annualized Adjusted EBITDA growth rate of at least 30% over the coming years."
Strata Critical Medical Enters $30M Credit Agreement with JPMorgan
Strata Critical Medical entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans in aggregate principal amount of up to $30M, which, subject to certain conditions, may be increased up to an aggregate of $50M.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。